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cardiac5 ischemia. In light of the positive results
obtained in these studies, clinical trials have been initi-
ated in patients with critical limb ischemia6-8 and severe
coronary artery disease.9-12 Although definitive results
on the therapeutic efficacy of these interventions are not
yet available, it has been reported that some patients
with severe peripheral vascular disease treated with the
intramuscular injection of plasmid DNA encoding the
165–amino acid form of VEGF have had limb edema
develop.7 This side effect was not unexpected because
VEGF is known to enhance vascular permeability.13-17
However, gene therapy studies in animal models have
failed to characterize this potentially clinically relevant
side effect of VEGF gene transfer.
The objective of this work was to evaluate the effects
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of the intramuscular injection of an adenovirus vector
coding for the 121–amino acid form of VEGF
(Ad.VEGF121) on vascular permeability and edema
development in rabbits and rats. The results show that
Ad.VEGF121 gene transfer to the skeletal muscle exerts
both local and systemic effects to transiently enhance
vascular permeability in the rabbit and that this response
is delayed several days with respect to increases in
VEGF serum level. Further, the development of edema
is species dependent and is not observed in the rat.
Methods
Replication-deficient adenovirus vectors. Ad.VEGF121
and the control vector (Ad.Null) have been previously
described18 and were supplied by GenVec (GenVec, Inc,
Rockville, Md). The viral vectors were stored in dialysis
buffer at –70°C. Solutions for intramuscular injection were
prepared immediately before use.
Animals. The experimental protocol was approved by the
Animal Care and Use Committee of the Gerontology
Research Center. Twenty-six male New Zealand White rab-
bits weighing 4.0 ± 0.5 kg (Human Research Products Inc
Rabbitry, Denver, Pa) and 14 male Wistar rats weighing 650
± 24 g (from the Gerontology Research Center’s Wistar rat
colony) were housed individually with constant access to
food (Purina Lab Rabbit Chow Diet [Ralston Purina
Company, St Louis, Mo] for rabbits and NIH-07 formula
[National Institutes of Health] for rats) and water. The tem-
perature in the vivarium was maintained at 22.5°C ± 1°C with
a 12-hour light/12-hour dark photocycle in which the light
came on at 6 AM.
Experimental design. In all experiments rabbits were
placed under general anesthesia with subdermal injection of
5 mg/kg xylazine and 40 mg/kg ketamine. Studies were car-
ried out according to the following experimental protocols.
Experimental protocol 1. Ad.VEGF121 was injected in the
muscles of the thigh of rabbits at 4 sites (0.25 mL per injec-
tion) along the projection of the femoral artery. Six concen-
trations of Ad.VEGF121 (105, 106, 107, 108, 109, and 1010
plaque-forming units (pfu/mL) and 2 concentrations of
Ad.Null (106 and 108 pfu/mL) were used. Each concentration
was injected into 2 animals. The size of the scrotum (area in
square centimeters) was measured before the injection and
daily during the 12 days after injection.
Experimental protocol 2. Rabbits received 4 intramuscular
injections of Ad.VEGF121 (0.25 mL per injection) into the
forelimb at the concentration 1010 pfu/mL. The size of the
scrotum and circumference of each forelimb were measured
before injection and daily during the 12 days after injection.
Blood (0.5 mL) was withdrawn daily from the marginal ear
vein for quantification of the concentration of the 121–amino
acid form of VEGF in the serum by enzyme-linked
immunosorbent assay.
Experimental protocol 3. Rats were placed under general
anesthesia with 60 mg/kg ketamine and 10 mg/kg xylazine
(intraperitoneally) and were injected with Ad.VEGF121 (109
pfu/mL) into each of 4 sites (0.25 mL per injection) of the
muscles of the thigh along the projection of the femoral
artery. The animals were examined daily for signs of edema.
Blood samples (0.3 mL) for the determination of the concen-
tration of the 121–amino acid form of VEGF in serum were
collected daily through a cardiac puncture with the rats under
general anesthesia.
Experimental protocol 4. The effects of Ad.VEGF121 on
vascular permeability in rabbits and rats were assessed with
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Fig 1. Edema of scrotum in rabbit. Representative example of time course of scrotal edema development in rab-
bit treated with intramuscular injection of 108 pfu Ad.VEGF121 into right thigh. Panels show scrotum of same ani-
mal before injection of viral vector (A) and at 6 (B) and 12 days (C) after exposure to Ad.VEGF121. Scales are in
centimeters.
the modified Miles assay.18,19 Because systemically injected
Evans blue dye binds specifically with albumin, it accumu-
lates in areas of increased vascular permeability. The change
in local concentration of Evans blue dye in response to the
intradermal injection of the investigated agent reflects the
effect of this agent on permeability. The effect of the condi-
tioned medium from human umbilical vein endothelial cells
(American Type Culture Collection, Manassas, Va) cultures
24 hours after infection with Ad.VEGF121 (100 pfu/cell) was
compared with that of conditioned medium from human
umbilical vein endothelial cells infected with Ad.Null (100
pfu/cell), uninfected cells, and saline solution. The concentra-
tion of VEGF in the conditioned medium of AdCMV.VEGF121
–infected human umbilical vein endothelial cells was 104
ng/mL. Evans blue dye (60 mg/kg; Fisher Scientific
Worldwide, Hampton, NH) was injected into the marginal ear
vein of rabbits or intracardially in rats. Immediately after the
injection of Evans blue dye the animals (6 rabbits and 6 rats )
received the intradermal injection of 0.1 mL saline solution
and 0.1 mL of each of the conditioned media. Other animals
(3 rats and 3 rabbits) received the intradermal injection of 0.1
mL histamine (105 ng/mL; Sigma, St Louis, Mo). All animals
were killed 30 minutes after injection. The skin from the areas
of local injections was cut out with a standard steel punch (1.0
cm in diameter) and placed into 4.0 mL formamide solution
(Fisher Scientific) at 65°C for 36 hours to extract the dye.
After filtration with glass filter (Pall Gelman Laboratory, Ann
Arbor, Mich), the optical density of the filtrate was measured
at 620A on a spectrophotometer (Beckman DU-50; Beckman
Coulter, Inc, Fullerton, Calif).
Enzyme-linked immunosorbent assay. Enzyme-linked
immunosorbent assay for quantification of the concentration
of the 121–amino acid form of VEGF in the serum was car-
ried out with human VEGF kit (Quantikine; R&D Systems,
Minneapolis, Minn). After withdrawal blood samples were
transferred from the syringe to collection tubes. The samples
were kept for 30 minutes at room temperature for clot forma-
tion and then spun at 4°C for 30 minutes at 10,000 rpm. The
serum from each tube was immediately frozen at –70°C. The
assay procedure was carried out according to the supplier’s
instructions. The concentration of VEGF was determined on
a spectrophotometer (Beckman DU-50) with a microtiter
plate reader set at the absorbance of 450 nm.
Statistical analyses. Results were evaluated with analyses
of variance for repeated measures (experimental protocols 1-
3). Between factors were different concentrations of
Ad.VEGF121 (protocol 1) or different sites of injection (pro-
tocol 2); the within factor was time (in days) after treatment.
Where appropriate the relative significance of difference
between groups was determined by analyses of simple
effects. The results of experimental protocol 4 were analyzed
by t test. P < .05 was accepted as statistically significant.
Results
Experimental protocol 1. Rabbits treated with intra-
muscular injection of Ad.VEGF121 in the hind limb had
scrotal edema develop (Fig 1) without gross evidence
of inflammation at the site of injection. The increase in
the size of the scrotum and the time courses of this
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Fig 2. Dose-response and time course of scrotal edema development in rabbits injected with Ad.VEGF121 in right
hind limb (experimental protocol 1). Two rabbits were injected with each concentration. Results are expressed as
percentage of scrotal size before injection and each rabbit served as its own control. Data points represent mean. 
effect in response to different concentrations of
Ad.VEGF121 are shown in Fig 2. Average scrotal size
before the intramuscular injection of Ad.VEGF121 was
7.5 ± 0.2 cm2 (mean ± SE, n = 12). The edema started
on day 3 after injection, reached its peak on days 6 and
7, and resolved spontaneously thereafter. There was no
significant edema at concentrations of 105 and 106
pfu/mL of Ad.VEGF121 (simple effect P = 1.0 and P =
.2 for each concentration, respectively). At higher con-
centrations statistically significant edema developed in
all animals and the time course of this effect was simi-
lar among groups (simple effects ranging from P = .002
for 107 pfu to P = .00001 for 1010 pfu). Furthermore,
the magnitude of the effect was dose dependent, rang-
ing from 2-fold at 107 pfu to 4.5-fold at 1010 pfu (P =
.004 for group effect, P = .00001 for time effect, and P
= .0001 for interaction). In the animals treated with
concentrations of 109 and 1010 pfu/mL the edema was
followed by skin necrosis in the scrotum (Fig 3). No
local inflammatory reactions and no signs of edema
were observed in rabbits treated with Ad.Null.
Experimental protocol 2. In additional experiments
(experimental protocol 2) it was examined whether the
edema was due to a systemic or localized effect of
Ad.VEGF121. In these studies rabbits were injected
with 1010 pfu/mL Ad.VEGF121 (4 injections of 250 m L
each) in the forelimb and the size of the scrotum was
measured in the ensuing days. In these experiments the
scrotum did not increase in size progressively after the
injection; rather, the edema developed abruptly on day
6 after the injection. (Fig 4). Average scrotal size before
the intramuscular injection of 1010 pfu of Ad.VEGF121
was 8.9 ± 1.2 cm2 (mean ± SE, n = 3). The edema was
less marked after injection in the forelimb than in the
hind limb, with 2-fold and 4-fold increases in the size
of the scrotum, respectively, and was not accompanied
by skin necrosis. Measurements of the circumferences
of the forelimbs are presented in Fig 5. Left and right
limb circumferences were similar, and average limb
circumference before the intramuscular injection of
1010 pfu Ad.VEGF121 was 11.3 ± 0.1 cm (mean ± SE,
n = 6). The circumferences of both forelimbs were
enhanced on day 6 after injection (significant group
and time effects and interaction, P = .001). The inject-
ed limb was more edematous than the contralateral
limb (137.2% ± 8.2% on injected side and 107% ±
7.0% on uninjected side with respect to preinjection
size). Nevertheless, the edema on both limbs was sta-
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Fig 3. Representative example of scrotal ulceration in rabbit 10 days after intramuscular injection of 1010 pfu
Ad.VEGF121. Scale is in centimeters.
tistically significant (simple effect P = .001 and P =
.005 for injected and uninjected limbs, respectively.
Experimental protocol 3. The other experiments
(experimental protocol 3) determined whether the
effect of Ad.VEGF121 to induce the edema was species
specific and peculiar to the rabbit or also occurred in
rats. Rats treated with intramuscular injections of
Ad.VEGF121 (109 pfu/mL) did not have any edema
develop (n = 3) at any time within the 15 days after
injection (data not shown).
The concentrations of VEGF in the serum after local
intramuscular injection of Ad.VEGF121 in rabbits (1010
pfu/mL, experimental protocol 2) and in rats (109
pfu/mL, experimental protocol 3) are shown in Fig 6, A
and B, respectively. In both species the concentration of
VEGF in the serum rose sharply on the second day
after injection and was markedly reduced by the third
day. It is noteworthy that the dose of Ad.VEGF121
injected in the rats was 10-fold less than in the rabbits,
to account for a body weight approximately 6-fold to
10-fold higher in the rabbit than in the rat.
Overall results. Taken together the results of this
study show that the intramuscular injection of
Ad.VEGF121 in the rabbit skeletal muscle exerts both
local and systemic effects to induce the edema and sug-
gest that this response may be species specific. This
point was further addressed (experimental protocol 4)
by performing a vascular permeability assay (Miles
assay) in both rats and rabbits. The quantitative
changes in local permeability in response to the intra-
dermal injection of conditioned medium containing
VEGF, medium from cells infected with Ad.Null, and
medium from uninfected cells for rabbits and rats are
presented in Fig 7. The increase in permeability in
response to VEGF-containing medium was approxi-
mately twice as large in rabbits than in rats (P = .01).
The response to the conditioned medium from cells
infected with Ad.Null was not different from the
response to the medium from uninfected cells for both
rabbits and rats and was significantly lower than the
response to medium containing VEGF (P = .005).
Additional experiments examined whether the
enhanced vascular permeability in response to VEGF
in rabbits in comparison with rats could also be
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Fig 4. Dose-response and time course of scrotal edema development in rabbits injected with 1010 pfu Ad.VEGF121
in right forelimb (experimental protocol 3). Results are expressed as percentage of scrotal size before injection
and each rabbit served as its own control. Data points represent mean; error bars indicate SE; n = 3.
observed after the intradermal injection of histamine,
another substance known to increase vascular perme-
ability. Similarly to the effects of VEGF, the intrader-
mal injection of 0.1 mL of a solution containing 105
ng/mL histamine caused twice as large a response in
rabbits as in rats (P = .05). Thus it appears that rats are
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Fig 6. Time course of levels of 121–amino acid form of VEGF in sera of rabbits injected with 1010 pfu
Ad.VEGF121 in forelimb (A, n = 3) and rats injected with 109 pfu Ad.VEGF121 in hind limb (B, n = 6). Data points
represent mean; error bars indicate SE.
A B
Fig 5. Dose-response and time course of forelimb edema development in rabbits injected with 1010 pfu Ad.VEGF121
in right forelimb (experimental protocol 3). Results are expressed as percentage of forelimb circumference before
injection and each forelimb served as its own control. Data points represent mean; error bars indicate SE; n = 3.
less likely than rabbits to have an increase in vascular
permeability develop in response to both VEGF and
histamine.
Discussion
VEGF, also known as vascular permeability factor, is
an endothelial cell–specific mitogen that induces
angiogenesis and vascular permeability in vitro and in
vivo. Although the angiogenic properties of VEGF
have been reported in several successful preclinical
animal studies1-5,14,20-22 and some phase 1 and 2 clini-
cal studies,7 little attention has been paid to its ability
to enhance vascular permeability, which may be
responsible for potentially clinically relevant side
effects of VEGF therapy.15,17,23,24
Our experiments showed that a single intramuscular
administration of Ad.VEGF121 caused the appearance
of VEGF in systemic circulation in rabbits and in rats 1
day after injection and led to a dose-dependent edema
in rabbits that reached its maximal level 6 days after the
injection. Additional experiments showed that the
effect of VEGF on tissue permeability was stronger in
rabbits than in rats.
The edema in rabbits was most marked on day 6 after
a single injection of Ad.VEGF121. In experiments in
which animals received injections into the thigh mus-
cles scrotal edema developed slowly, reaching its maxi-
mum on day 6. When the site of injection was remote
from the scrotum (front limb), the scrotal edema
appeared more abruptly on day 6 after injection. The
different time courses of the scrotal edema after injec-
tion at different sites suggest that increase in permeabil-
ity is initiated at the site of injection of Ad.VEGF121.
Permeability increases gradually, on day 6 reaching a
degree that affects remote sites susceptible to the effect
of increased permeability. This notion is compatible
with the properties of adenoviral vectors, with which
expression peaks within 7 days after infection.25 The
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Fig 7. Effects of 121–amino acid form of VEGF in vascular permeability assay in rabbits and rats. Interventions
were intradermal injection of 0.1 mL conditioned medium containing 104 ng/mL 121–amino acid form of VEGF
(V), uninfected cells (UNINF), or cells infected with Ad.Null (NULL). Boxes represent mean; error bars indicate
SE; n = 6.
increased concentration of VEGF in the serum on the
first day is a temporary overexpression from the local
intramuscular injection. After that the virus infects the
cells without significant access to systemic circulation.
The increase of vascular permeability caused by
VEGF16,17 is related to endothelial cell activation
caused by synthesis and release of mediators of the
prostaglandin family. In a variety of cell types the
growth factor activates phospholipase A2 and induces
the release of arachidonic acid and platelet activating
factor within minutes. Moreover, it has been found that
VEGF-induced protein extravasation is dose and tissue
dependent and is inhibited by a selective platelet acti-
vating factor receptor antagonist. VEGF binds specifi-
cally to the endothelial cell growth tyrosine kinase
receptors but not to other cell types. However, the con-
centration of receptors is not homogeneous and may
vary among different tissues. The luminal surfaces of
bronchial and pulmonary arteries possess the highest
density of VEGF-binding sites, blood vessels of the
pancreas and small intestine show a strong affinity for
VEGF, and the most vascularized renal papillae have
the highest degree of binding.16 It has been shown that
lower concentrations of VEGF induce extravasation in
the trachea and pancreas and that in increased doses it
affects vascular permeability in the bronchi and duode-
num. However, extravasation of protein in the lung
parenchyma, heart, liver, and spleen has not been asso-
ciated with intravenous injection of either VEGF or
platelet activating factor.
VEGF-induced vascular permeability is an enhance-
ment of vesicular-vacuolar organelle activity, which
plays an important role in transendothelial transport of
macromolecules.13 Connolly26 speculated that on bind-
ing of VEGF with its receptors cytoskeletal changes
would lead to cell contraction and increased intracellu-
lar vascular permeability. Another study has shown that
VEGF is able to induce fenestration in endothelial cells
in vivo and to convert endothelium from a nonfenestrat-
ed type into a fenestrated type.27 The increased vascular
permeability during the growth of tumor vasculature
leads to flow of the bulk of fluid into the surrounding
extracellular space.28 Physiologically this means an
excessive enlargement of the extravascular space. The
tropism of the edema toward the scrotum may be
explained by particularities of scrotal anatomic struc-
ture. The scrotum in rabbits is isolated from the body
and does not have strong tissue support. It is among the
richest areas of connective tissue spaces and lymphatic
supply, which facilitate the accumulation of fluid.
In recent experiments on angiogenic effects of
Ad.VEGF121 in a rabbit hind limb ischemia model, a
significant acceleration of restoration of blood flow was
observed after treatment with concentrations of 106 and
108 pfu/mL (unpublished data). These concentrations
produced insignificant or spontaneously reversible scro-
tal edema. The massive scrotal edema accompanied by
skin ulceration and necrosis was observed only with
concentrations that exceeded those required for the ther-
apeutic effects. Because a single local administration of
VEGF was efficacious in stimulating angiogenesis and
because therapeutic doses of Ad.VEGF121 resulted in
only moderate transient scrotal edema in rabbits, we
conclude that the potential for side effects of VEGF
therapy as a result of increased vascular permeability
are minimal in generally healthy organisms and may not
cause a significant clinical problem for treatment of
peripheral vascular diseases. We did not observe any
obvious changes in the respiratory and renal function of
animals injected with Ad.VEGF121. Nevertheless, it is
conceivable that these areas might be more vulnerable
to treatment-related complications. In the case of
patients with compromised heart function, the increased
permeability caused by VEGF therapy should increase
alertness for pulmonary edema.
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